<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501693</url>
  </required_header>
  <id_info>
    <org_study_id>FMSU2017-002B</org_study_id>
    <nct_id>NCT03501693</nct_id>
  </id_info>
  <brief_title>Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study</brief_title>
  <official_title>A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujifilm Medical Systems USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujifilm Medical Systems USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the pivotal reader study is to assess the comparative accuracy of Fujifilm DBT
      plus S-View versus FFDM in the detection of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical research is a retrospective, pivotal, multi-reader, multi-case (MRMC) study
      with an enriched sample of 300 breast screening or diagnostic cases which were selected from
      the library of mammograms collected under Fujifilm protocol FMSU2013-004A (all subjects
      previously provided written informed consent agreeing their image data and supporting
      documentation could be used for future research and investigations). Approximately 18
      qualified radiologists will independently perform two reads on all (approximately 300) cases.
      Each reader will read each case both as a FFDM read, and a DBT plus S-View read on the ASPIRE
      Bellus II workstation.

      As its primary endpoint, this study is designed to evaluate whether the area under the
      receiver operating characteristic (ROC) curve (AUC) based on probability of malignancy (POM)
      scores and requiring correct lesion localization is statistically non-inferior for DBT plus
      S-View versus FFDM.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferior per subject AUC</measure>
    <time_frame>There will be two, 3 day long reader sessions; separated by an approximate 4 week long washout period.</time_frame>
    <description>Non-inferior per subject AUC: DBT plus S-View versus FFDM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-inferior per-subject average recall rate for all non-cancer cases for DBT plus S-View versus FFDM</measure>
    <time_frame>There will be two, 3 day long reader sessions; separated by an approximate 4 week long washout period.</time_frame>
    <description>based on recall scores, using non-inferiority margin delta = 0.05.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferior per-subject average recall rate for DBT plus S-View versus FFDM for all cancer cases</measure>
    <time_frame>There will be two, 3 day long reader sessions; separated by an approximate 4 week long washout period.</time_frame>
    <description>based on recall score, using non-inferiority margin delta = 0.10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferior per-subject average sensitivity for DBT plus S-View versus FFDM</measure>
    <time_frame>There will be two, 3 day long reader sessions; separated by an approximate 4 week long washout period.</time_frame>
    <description>based on BI-RADS scores requiring correct lesion localization, using non-inferiority margin delta = 0.10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>DBT plus S-View</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast images utilizing DBT plus S-View</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFDM alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FFDM alone images</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBT plus S-View</intervention_name>
    <description>DBT plus S-View images</description>
    <arm_group_label>DBT plus S-View</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFDM Alone</intervention_name>
    <description>FFDM alone images</description>
    <arm_group_label>FFDM alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  •Female subjects participating in FMSU2013-004A protocol with known clinical status

        Exclusion Criteria:

          -  •Female subjects that did not have known clinical status in FMSU2013-004A
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>International HealthCare, LLC</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

